TransMedics Group (NASDAQ:TMDX) Trading Up 7.4% - Should You Buy?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) traded up 7.4% on Monday . The company traded as high as $86.60 and last traded at $86.54. 907,876 shares changed hands during trading, a decline of 32% from the average session volume of 1,332,665 shares. The stock had previously closed at $80.58.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on TMDX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Wednesday, March 26th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $122.70.

TransMedics Group Stock Up 3.3 %

The firm's fifty day moving average is $72.48 and its 200-day moving average is $79.89. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock has a market capitalization of $2.98 billion, a P/E ratio of 93.87 and a beta of 2.14.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors have recently bought and sold shares of TMDX. NBC Securities Inc. acquired a new stake in shares of TransMedics Group in the first quarter valued at $25,000. Atlas Capital Advisors Inc. bought a new stake in TransMedics Group during the 4th quarter worth about $31,000. Hager Investment Management Services LLC acquired a new stake in TransMedics Group in the 4th quarter valued at about $33,000. Sachetta LLC bought a new position in shares of TransMedics Group in the fourth quarter worth about $40,000. Finally, AlphaQuest LLC acquired a new position in shares of TransMedics Group during the fourth quarter worth approximately $52,000. Institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.